Skip to main content
Figure 3 | BMC Cancer

Figure 3

From: Mitogen activated protein kinase kinase kinase 3 (MAP3K3/MEKK3) overexpression is an early event in esophageal tumorigenesis and is a predictor of poor disease prognosis

Figure 3

Evaluation of MEKK3 overexpression as a prognostic marker in ESCC. Kaplan–Meier estimation of cumulative proportion of disease-free survival: (a) Median time for disease-free survival (DFS; no recurrence/metastasis) in patients showing increased MEKK3 expression (shown with solid line) DFS was 10 months and was significantly reduced as compared to patients with ESCC that showed no or mild immunostaining (p = 0.005; median DFS = 19 months, shown with dotted line); (b) Median time for disease-free survival (DFS; no recurrence/metastasis) in patients showing increased MEKK3 expression and lymph node positivity (shown with solid line) DFS was 9 months and was significantly reduced as compared to patients with ESCC that showed no or mild immunostaining (median DFS = 21 months; range 1–90 months p = 0.01; shown with dotted line).

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us